Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01705977 · ClinicalTrials.gov registry record · Phase 4

Belimumab Assessment of Safety in SLE

A Phase 4 study of Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
4,019
Enrollment target
20
Study locations

NCT01705977 is a Phase 4 study of Systemic Lupus Erythematosus that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,019 participants, above the 340-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1082% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01705977, a Phase 4 study of Systemic Lupus Erythematosus, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
4,019 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that common or may only be seen with long-term treatment. These events include death, serious infections and other infections of interest, cancers, serious mental health problems, including depression and suicide, and serious infusion and hypersensitivity reactions. This study is being done to help understand if treatment with belimumab increases the risk for these types of events. This study will also see if patients receiving belimumab with other lupus medicines can reduce their use of steroids, such as prednisone, over 1 year.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • BIOLOGICAL Placebo plus standard therapy
  • BIOLOGICAL Belimumab 10 mg/kg plus standard therapy
  • OTHER Standard therapy

Study Locations (20)

California

  • GSK Investigational Site - Covina
  • GSK Investigational Site - Huntington Beach
  • GSK Investigational Site - La Mesa
  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Murrieta
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Leandro

Arizona

  • GSK Investigational Site - Glendale
  • GSK Investigational Site - Mesa
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix

Alabama

  • GSK Investigational Site - Anniston
  • GSK Investigational Site - Birmingham
  • GSK Investigational Site - Huntsville

Florida

  • GSK Investigational Site - Clearwater
  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Tampa

Iowa

  • GSK Investigational Site - Cedar Rapids

Michigan

  • GSK Investigational Site - Saint Clair Shores

Trial Details

FieldValue
Enrollment Target 4,019 participants
Start Date 2012-11-27
Est. Completion 2022-08-10
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01705977

The ClinicalTrials.gov registry entry for NCT01705977 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4,019 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 340-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1082% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 3 interventions - of which Placebo plus standard therapy is the first listed.

NCT01705977 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT01705977 about?

NCT01705977 is a clinical study titled "Belimumab Assessment of Safety in SLE". The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that commo...

What is the current status of trial NCT01705977?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,019 participants. The study started on 2012-11-27. Estimated completion is 2022-08-10.

What conditions does trial NCT01705977 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT01705977?

The interventions under investigation include: Placebo plus standard therapy (BIOLOGICAL), Belimumab 10 mg/kg plus standard therapy (BIOLOGICAL), Standard therapy (OTHER).

Who is sponsoring clinical trial NCT01705977?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01705977 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.